Discover 1,147 paid clinical trials in New Haven, Connecticut. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,147
Active & Responsive
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Location: New Haven CT, Mineola NY, New York NY, New Brunswick NJ,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT03816345
Phase1, Recruiting
Active & Responsive
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
for
Plasma Cell Myeloma
Location: New Haven CT, North Haven CT, Derby CT, Guilford CT,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 0+
Code: NCT05561387
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
for
Metastatic Breast Cancer
Location: New Haven CT, North Haven CT, Derby CT, Guilford CT,
Sponsor: American Society of Clinical Oncology
Sex: All
Age: 60+
Code: NCT06377852
Phase3, Recruiting
Active & Responsive
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
for
Non-small Cell Lung Cancer
Location: New Haven CT, White Plains NY, Albany NY,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT07513376
Phase3, Recruiting
Active & Responsive
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
for
Glioblastoma
Location: New Haven CT, New York NY, Boston MA, Montreal, Toronto,
Sponsor: Global Coalition for Adaptive Research
Sex: All
Age: 18+
Code: NCT03970447
Phase2, Phase3, Recruiting
Active & Responsive
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Location: New Haven CT, Lake Success NY, The Bronx NY,
Sponsor: Black Diamond Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT07326566
Phase2, Recruiting
Active & Responsive
Efficacy and Safety Evaluation of VS-101 in Combination With Chemoradiotherapy in Patients With Head and Neck Cancer
for
Head and Neck Cancer Squamous Cell Carcinoma
Location: New Haven CT, Manhattan NY
Sponsor: VSPharmTech Co.,Ltd.
Sex: All
Age: 18+
Code: NCT06959082
Phase2, Recruiting
Active & Responsive
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
Location: New Haven CT, Philadelphia PA, Fairfax VA,
Sponsor: Ipsen
Sex: All
Age: 18+
Code: NCT07213817
Phase1, Phase2, Recruiting
Active & Responsive
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
for
Solid Tumor Malignancies
Location: New Haven CT, Fairfax VA, Cleveland OH, Jacksonville FL,
Sponsor: Kumquat Biosciences Inc.
Sex: All
Age: 18+
Code: NCT06994806
Phase1, Recruiting
Active & Responsive
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
for
PIK3CA Mutation, HER2- Negative Breast Cancer,
Location: New Haven CT, New York NY, Hackensack NJ,
Sponsor: Relay Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT06982521
Phase3, Recruiting
Active & Responsive
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
for
Prostate Cancer, Prostatic Neoplasms
Location: New Haven CT, West Haven CT, New York NY, Hackensack NJ,
Sponsor: Merck Sharp & Dohme LLC
Sex: Male
Age: 18+
Code: NCT06925737
Phase3, Recruiting
Active & Responsive
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies